China's WuXi AppTec H1 revenue rises,  raises 2026 guidance

WuXi AppTec

03/08/2026 17:35

Repeats to additional subscribers; no changes to text

Overview
China pharmaceutical R&D services firm's H1 revenue rose 38.9% yr/yr to RMB 28.9 bln
Net profit attributable to owners grew 33.7% yr/yr; adjusted non-IFRS net profit attributable to owners up 83.2%
Company declared a mid-year dividend for the reporting period

Outlook
WuXi AppTec raises 2026 total revenue guidance to RMB58.5 to 60.5 bln, up from RMB51.3 to 53.0 bln
Company expects 2026 continuing operations revenue to grow 35%-39% YoY, up from 18%-22%
WuXi AppTec raises 2026 capex forecast to RMB7.5-8.5 bln and adjusted free cash flow to RMB13.5-14.5 bln

Result Drivers
CHEMISTRY SEGMENT GROWTH - Revenue from WuXi Chemistry rose 53.3% yr/yr, driving overall growth
GLOBAL PRESENCE & CHAIN COVERAGE - Co said leveraging global presence and full industrial chain coverage enabled it to seize new business opportunities
INTEGRATED SERVICE PLATFORM - Co said its integrated end-to-end R&D service platform advanced customer projects and supported sustained growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 28.9 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for WuXi AppTec Co Ltd is HK$169.90, about 4.3% above its August 3 closing price of HK$162.90
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
July 31 - AbbVie beats Q2 revenue, adjusted EPS estimates but cuts FY adj EPS guidance
July 31 - Moderna posts smaller-than-expected Q2  loss per share on lower R&D spending 
July 31 - Tenax Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)